Viatris Dirección
Dirección controles de criterios 3/4
El CEO de Viatris es Scott Smith , nombrado en Apr 2023, tiene una permanencia de 3.08 años. compensación anual total es $15.27M, compuesta por 9.5% salario y 90.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $19.99M. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 4.5 años, respectivamente.
Información clave
Scott Smith
Chief Executive Officer (CEO)
US$15.3m
Compensación total
| Porcentaje del salario del CEO | 9.48% |
| Permanencia del CEO | 3.1yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 2.1yrs |
| Promedio de permanencia en la Junta Directiva | 4.5yrs |
Actualizaciones recientes de la dirección
Recent updates
VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential
Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan?
Mar 20
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Viatris: One Swallow Doesn't Make A Summer
Feb 27Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Jan 24Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Jan 06Bargain Priced Viatris Reports Strong Q3 Earnings Results
Nov 08Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Oct 22Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2025 | US$15m | US$1m | -US$4b |
| Sep 30 2025 | n/a | n/a | -US$4b |
| Jun 30 2025 | n/a | n/a | -US$3b |
| Mar 31 2025 | n/a | n/a | -US$4b |
| Dec 31 2024 | US$15m | US$1m | -US$634m |
| Sep 30 2024 | n/a | n/a | -US$883m |
| Jun 30 2024 | n/a | n/a | -US$646m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$16m | US$1m | US$55m |
Compensación vs. Mercado: La compensación total ($USD15.27M) de Scott está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD14.58M).
Compensación vs. Ingresos: La compensación de Scott ha aumentado mientras la empresa no es rentable.
CEO
Scott Smith (63 yo)
3.1yrs
Permanencia
US$15,273,331
Compensación
Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | US$15.27m | 0.11% $ 20.0m | |
| Chief Financial Officer | 2.2yrs | US$5.59m | 0.0061% $ 1.1m | |
| Chief Administrative & Transformation Officer | less than a year | US$4.30m | 0.019% $ 3.3m | |
| Chief Commercial Officer | 2.1yrs | US$5.93m | 0.0092% $ 1.6m | |
| Chief Accounting Officer & Corporate Controller | 11yrs | US$5.52m | 0.031% $ 5.5m | |
| Chief Information Officer | 2.2yrs | sin datos | sin datos | |
| Head of Investor Relations & Capital Markets | no data | sin datos | sin datos | |
| Chief Legal Officer | less than a year | sin datos | 0% $ 0 | |
| Chief People & Corporate Affairs Officer | less than a year | sin datos | sin datos | |
| Chief R&D Officer | 2.4yrs | sin datos | sin datos | |
| Chief Supply Officer | 2.1yrs | sin datos | sin datos | |
| Chief Strategy Officer | 1.1yrs | sin datos | sin datos |
2.1yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VTRS se considera experimentado (2.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 3.4yrs | US$15.27m | 0.11% $ 20.0m | |
| Independent Non-Executive Director | 6.3yrs | US$475.01k | 0.0088% $ 1.5m | |
| Independent Director | 5.5yrs | US$395.01k | 0.0096% $ 1.7m | |
| Independent Director | 3.4yrs | US$395.01k | 0.0054% $ 942.2k | |
| Independent Director | 5.5yrs | US$445.01k | 0.014% $ 2.4m | |
| Independent Director | 1yr | US$374.93k | 0.0022% $ 392.3k | |
| Independent Non-Executive Chairman | 13.3yrs | US$720.01k | 0.019% $ 3.3m | |
| Independent Vice Chairman & Lead Independent Director | 16.7yrs | US$525.01k | 0.014% $ 2.5m | |
| Independent Director | 1.9yrs | US$375.01k | 0.0040% $ 700.5k | |
| Independent Director | 1yr | US$324.93k | 0.0022% $ 392.3k | |
| Independent Director | 6.3yrs | US$445.01k | 0.010% $ 1.7m | |
| Independent Director | 3yrs | US$400.01k | 0.0054% $ 954.5k |
4.5yrs
Permanencia media
63.5yo
Promedio de edad
Junta con experiencia: La junta directiva de VTRS se considera experimentada (4.5 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/04 08:59 |
| Precio de las acciones al final del día | 2026/05/04 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Viatris Inc. está cubierta por 31 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |